Cara Therapeutics (CARA)
(Delayed Data from NSDQ)
$0.30 USD
0.00 (-0.33%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $0.29 -0.01 (-3.65%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.30 USD
0.00 (-0.33%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $0.29 -0.01 (-3.65%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum C VGM
Zacks News
TFF Pharmaceuticals, Inc. (TFFP) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TFF Pharmaceuticals (TFFP) delivered earnings and revenue surprises of 28.24% and 333.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Ovid Therapeutics (OVID) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 154.55% and 20.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcellx (ACLX) delivered earnings and revenue surprises of 5.56% and 1.23%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of -47.37% and 5.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of -3.51% and 28.60%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
CARA's Late-Stage Skin Disease Study Fails, Stock Plummets 49%
by Zacks Equity Research
CARA discontinues the clinical program of oral difelikefalin for pruritus associated with atopic dermatitis following the failure of dose-finding Part A of the late-stage study. Stock plunges 49%.
Cara (CARA) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Cara (CARA) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Cara Therapeutics (CARA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of -3.57% and 6.79%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Twist Bioscience (TWST) delivered earnings and revenue surprises of 11.40% and 5%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics (CARA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of 7.55% and 22.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 10% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
scPharmaceuticals, Inc. (SCPH) delivered earnings and revenue surprises of 16.67% and 20.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -0.66% and 37.92%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics (CARA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of -69.70% and 76.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Cara Therapeutics (CARA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of -2.38% and 28.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Cara Therapeutics (CARA) Might Surprise This Earnings Season
by Zacks Equity Research
Cara Therapeutics (CARA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Analysts Estimate Affimed N.V. (AFMD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Affimed N.V. (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cara Therapeutics (CARA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Cara (CARA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts See a 133% Upside in Cara (CARA): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Cara (CARA) points to a 132.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of 71.43% and 8.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Cara Therapeutics (CARA) Ahead of Earnings?
by Zacks Equity Research
Cara Therapeutics (CARA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of 7.14% and 69.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?